Calypso® Medical Exhibits at American Urological Association Annual Meeting

The highly accurate prostate tumor tracking technology, Calypso® Medical’s 4D Localization System, will be on display at Booth #3924

SEATTLE and CHICAGO—April 23, 2009—Calypso® Medical Technologies, Inc., a medical device company dedicated to shaping the future of radiation therapy delivery and management, today announced that it will exhibit at the American Urological Association’s Annual Meeting, which takes place April 25 to 28 at McCormick Place in Chicago. During the meeting, the Calypso® 4D Localization System™ and implantable Beacon® transponders will be on display at booth #3924. Urologists across the country have implanted thousands of patients with Beacon® transponders in their effort to ensure state of the art prostate cancer care.

Calypso Medical’s proprietary technology, known as GPS for the Body®, utilizes minute implanted transponders to provide precise, continuous real-time information on the location of the tumor during prostate external beam radiation therapy and for post-operative prostatic bed patients experiencing a recurrence of disease. Any movement by the patient, including internal movement of the tumor, may cause the radiation to miss its intended target and hit surrounding healthy tissue. In contrast to other tumor targeting solutions, GPS for the Body technology provides continuous tumor position information, objectively and without additional ionizing radiation, thereby enabling optimization of the delivery of radiation to the tumor and minimization of misapplied radiation to normal tissue.

“Improving patient care was the key reason we purchased a Calypso System when we built our state-of-the-art radiation therapy center,” said Dr. Richard Harris of UroPartners in Glenview, Illinois. “Delivering the right dose of radiation while minimizing side effects is critical to any urologist who follows patients after radiation treatment.”

In addition to use in the prostate, the Calypso System received FDA 510k clearance for use in the post-operative prostatic bed in May 2008. Extraprostatic disease will manifest itself in one-third of men after radical prostatectomy, per the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) study. A long-term randomized clinical trial conducted by Dr. Ian Thompson, lead author of the study and Chairman of Urology at the University of Texas Health Science Center, suggests that the addition of adjuvant radiotherapy within 18 weeks following radical prostatectomy in men with Stage III (pT3N0M0) prostate cancer significantly reduces the risk of PSA recurrence, metastasis, the need for hormonal therapy, and significantly increases survival.

“Upwards of 30 percent of men undergoing prostatectomy for prostate cancer will experience PSA evidence of relapse at some time following their surgery. These men will be candidates for radiation treatment directed to the prostatic bed in an effort to cure them of their recurrent tumor,” said Dr. Kenneth Russell, M.D., Medical Director, Radiation Oncology at the Seattle Cancer Care Alliance. “The technical challenges of postoperative radiation are the same as in the treatment of men with intact prostates: accuracy of treatment for a variably and unpredictably moving target and protection of nearby bladder and bowel. The Calypso System’s localization and tracking technology addresses these issues head-on and provides a powerful tool for the treatment of men in this clinical setting.”